Depression: all studies (page 55) - The Consciousness Library

Ketamine in the treatment of bipolar depression

Brazilian Journal of Health Review January 28, 2026 Juliana Chies Galvan, Marina Chies Galvan, Rafael Moreno Ferro de Araújo

Bipolar depression is the most prevalent state throughout the life of the bipolar patient, even so, few studies have focused on the treatment of depression in this population. Between the available medications approved for treatment of bipolar depression, ketamine is an option that must be considered. The purpose of this paper was to review the scientific evidence on the efficacy of using...

DOI: 10.34119/bjhrv9n1-120

Modulating tonic NMDA receptor currents: mechanistic insights into ketamine, esketamine, and dextromethorphan for major depressive disorder and implications for the discovery and development of investigational agents.

Expert Opinion on Therapeutic Targets January 28, 2026 Gia Han Le, Roger S McIntyre 1 citation

Up to 50% of adults with major depressive disorder (MDD) fail to achieve remission after two or more monoaminergic antidepressants and meet criteria for treatment-resistant depression (TRD). Low-dose intravenous ketamine, intranasal esketamine, and oral dextromethorphan represent the first glutamatergic treatments to exhibit rapid and robust efficacy in persons with TRD, yet their precise...

DOI: 10.1080/14728222.2026.2619757 Full text Treatment-resistant depression Esketamine Nmda receptor subunits Antidepressant mechanisms +2

Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies.

Journal of Affective Disorders January 28, 2026 Clara De Oliveira Lapa, Thiago Viola, Rodrigo Delfino et al. 3 citations

Intranasal esketamine has demonstrated efficacy and safety for treatment-resistant depression in randomized controlled trials, however the generalizability of these findings to clinical practice remains unclear. This systematic review and meta-analysis aimed to synthesize real-world evidence of intranasal esketamine in patients with treatment-resistant depression. A systematic search was...

DOI: 10.1016/j.jad.2026.121257 Full text Esketamine Treatment-resistant depression Intranasal Meta-analysis +2

PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION

International Journal of Innovative Technologies in Social Science January 28, 2026 Łukasz Deska, Cezary Kosmecki, Dawid Głaz et al.

This manuscript comprehensively reviews psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression. It aims to synthesize current understanding regarding its mechanisms, efficacy, safety, costs, and accessibility, comparing it with conventional antidepressant and ketamine treatments. The methodology involved a narrative synthesis of academic literature, drawing...

DOI: 10.31435/ijitss.1(49).2026.4711 Psilocybin Major depressive disorder Treatment-resistant depression Ketamine +9

Astroglia and depression: A Gliocentric perspective from rodent models to therapeutic insights.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 27, 2026 Rhea Subba, Surendar Ellappan, Sugato Banerjee et al.

Major depressive disorder (MDD) is a debilitating neuropsychiatric condition that affects individuals worldwide. While neuronal deficits have long been recognized in depression pathogenesis, astroglia are increasingly gaining attention. Astroglia are essential for maintaining brain homeostasis, and regulate neurotransmission, neuroinflammation, and metabolic processes that are disrupted in MDD....

DOI: 10.1016/j.pnpbp.2026.111627 Full text Depression Ketamine Major depressive disorder Antidepressants +4

The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidence

Zenodo (CERN European Organization for Nuclear Research) January 26, 2026 Fernando Mora López, Johynny Solís Solís, Ekaterina Daniela Hernández Baker et al. preprint

This review examines the therapeutic efficacy of psilocybin for major depressive disorder by integrating findings from clinical trials, meta-analyses, and mechanistic research. A comprehensive literature search across major scientific databases identified empirical studies evaluating psilocybin’s effects on depressive symptomatology, safety, and underlying neurobiological mechanisms....

DOI: 10.5281/zenodo.18375716 Psilocybin Default mode network Major depressive disorder Neuroplasticity +10

The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression

Emerging Minds Journal for Student Research January 25, 2026 Rishika Scott, James Smith

Treatment-resistant depression (TRD) has been well-researched within scientific literature, although the therapeutic value of psilocybin is not fully understood. The aim of this systematic review is to determine a stable and effective dosage unit to inform health professionals of the benefits of psilocybin, using peer-reviewed literature and meta-analysis. The review will also compare selective...

DOI: 10.59973/emjsr.317 Psilocybin Dosing Depression economics Clinical trial +4

Serial ketamine infusions not effective as adjunctive care for depression

The Brown University Psychopharmacology Update January 24, 2026

Up to eight infusions of ketamine were not more effective than a psychoactive placebo in reducing depressive symptoms in patients receiving inpatient treatment for depression, a randomized trial has found. Patients receiving ketamine also showed no improvement relative to those receiving midazolam on measures of cognition and quality of life. Study results were published online Oct. 22, 2025 in...

DOI: 10.1002/pu.31401 Ketamine Depression economics Placebo Midazolam +6

Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis

Neuroscience & Biobehavioral Reviews January 24, 2026 Omer A. Syed, Benjamin Tsang, Sean M. Nestor et al.

Psilocybin-assisted therapy (PAT) is an emerging intervention for depression. Though several clinical trials report promising results for PAT in treating depression, there remains a need for consensus on optimal methodologies and standardization of PAT protocols. The objective of this review was to assess the efficacy of PAT in treating depressive symptoms and to systematically examine the...

DOI: 10.1016/j.neubiorev.2026.106573 Treatment-resistant depression Major depressive disorder Psilocybin Antidepressant +13

Long-term effectiveness and side-effects of intranasal esketamine in treatment-resistant depression: real-world, single-arm study of over 100 sessions.

BJPsych Open January 23, 2026 Nawfel Ayad, Karim Abdel Aziz, Samer Makhoul et al. 2 citations

Treatment-resistant depression (TRD) poses a significant clinical challenge, with limited evidence guiding long-term pharmacological strategies. Esketamine, a glutamatergic modulator, has demonstrated short-term efficacy in TRD, but data on its extended use in real-world settings remains scarce. This study aimed to evaluate the long-term effectiveness and side-effects of intranasal esketamine...

DOI: 10.1192/bjo.2025.10950 Full text Treatment-resistant depression Esketamine Long-term effectiveness Maintenance therapy +1